- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
-Top executive brings over 20 years of experience in consumer med-tech products
-Most recently responsible for annual sales of USD 500 million
-"SimpliClear is a breakthrough innovation delivering aesthetic benefit and superior clinical outcomes to orthodontic appliances"
David Edwards is the new Chief Executive Officer of the Singaporean Nanostart (OTCQX: NASRY) holding BioMers Pte Ltd. The top executive will be leveraging his extensive experience in building brands to drive BioMers' commercial expansion and launch of flagship product, SimpliClear™. The SimpliClear product range is the world's only completely translucent orthodontic system. Mr. Edwards is based in BioMers‘ Singapore headquarters and is responsible for the company‘s worldwide business, reporting to the Board of Directors.
Mr. Edwards brings broad management experience and global brand development expertise in the consumer and med-tech space to the company, and has an impressive track record in growing businesses in the US, Europe and Asia.
Most recently, Mr. Edwards was responsible for annual sales of over USD 500 million as the President of Asia-Pacific at Bausch & Lomb, one of the leading producers of eye health products, responsible for the Asian eye health portfolio. Under his leadership, Bausch & Lomb's business in Asia was turned around and new products were successfully launched. Bausch & Lomb has more than 10,000 employees across 35 countries. Its total revenues amount to more than USD 2 bn.
Mr. Edwards also spent more than ten years with Johnson & Johnson in several top management positions. This includes leading roles as business unit head at Johnson & Johnson's diabetes business (encompassing Western Europe, Eastern Europe, Middle East and Africa), the vision care business (Asia Pacific, including China and India) and the consumer nutritionals business (Europe). He achieved strong growth in his relevant areas, with the successful launch of numerous products and product innovations. Johnson & Johnson has around 140,000 employees worldwide across 57 countries. In 2010 the company achieved revenues of about USD 62 bn.
Further positions include local, regional and global roles at Nestlé in the US, in Europe and at the global headquarters in Vevey, Switzerland.
David Edwards comments on his new position: "I am looking forward to my new role at BioMers. SimpliClear is a proven product, which has been long awaited by orthodontists and patients. It represents a breakthrough innovation in the growing market for aesthetic orthodontic appliances and delivers superior clinical outcomes."
Andreas Kröll, managing director of Nanostart Asia, comments: "We are excited that David Edwards has joined us as CEO of BioMers. His impressive experience and highly efficient management style combine with the SimpliClear product to create ideal conditions for blockbuster business success - and ensure a solid foundation for BioMers success."
David Edwards succeeds Dr. Mervyn Fathianathan as CEO. Dr. Fathianathan is one of the founders and a director of BioMers. He will continue as the CTO of BioMers, and shall be responsible for customer and product development. He added: "With David Edwards, we have brought a top executive into BioMers who will contribute to make the company a global leader in orthodontics. His commitment highlights the value of our products and company. This marks the start of rapid expansion of the company's business on a global scale."
Nanostart holds its position in BioMers through the Nanostart Singapore Early Stage Venture Fund. The fund's shareholding in BioMers is about 25 percent.
About Nanostart AG
Nanostart AG (OTCQX: NASRY), headquartered in the German financial capital of Frankfurt, is the world’s leading nanotechnology investment company, with portfolio companies spanning the globe from Silicon Valley to Singapore. The company provides venture capital financing for nanotechnology companies in various growth phases with a focus on innovation-driven industries of the future such as cleantech, life sciences and IT/electronics. Through its subsidiary and venture capital fund in Singapore, Nanostart is proud to be the investment partner of the Singaporean government. For further information, please visit www.nanostart.de.
BioMers is a medical device company that has developed novel polymer composite products for numerous biomedical applications. The company’s flagship product is the SimpliClear™ braces system, which is the world’s first and only aesthetic solution for all types of orthodontic treatments. This translucent, almost invisible braces system is customized to each patient, providing faster and better results. Established in 2005, BioMers is a spin-off company from the National University of Singapore, where the technology was invented. BioMers has received seed funding from NUS Enterprise, venture capital funding from the Nanostart Singapore Early Stage Venture Fund, and grants from government agencies, including SPRING Singapore and the Economic Development Board. For more information, visit www.biomersbraces.com
This notice constitutes neither an offer to sell nor a solicitation of offers to purchase or subscribe to securities. There will be no public offering of securities of Nanostart AG in conjunction with the existing listing of its shares in the “Entry Standard” segment of the regulated unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This notice does not constitute a securities prospectus. Neither this notice nor the information contained within is intended for direct or indirect distribution within Canada, Australia or Japan.
For more information, please click here
Dr. Hans Joachim Duerr
Head of Corporate Communications
D-60313 Frankfurt am Main
phone: +49 (0)69-21 93 96 111
fax: +49 (0)69-21 93 96 150
Copyright © Nanostart AGIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Graphenea celebrates fifth anniversary April 27th, 2015
Harris & Harris Group Sponsors NYC American Heart Association's Health Sciences Innovation Investment Forum: Co-founder of Harris & Harris Group Portfolio Company TARA Biosystems to Speak About the Value of Tissue Engineering Technology April 21st, 2015
Long Island Capital Alliance Announces Participants for Brookhaven National Laboratory Technology Transfer Capital Forum on May 8: Keynote Speaker Dr. Doon Gibbs, Director of Brookhaven National Laboratory April 16th, 2015
Graphenea celebrates fifth anniversary April 27th, 2015
Dais Analytic Corporation Appoints Eliza Wang to Board of Directors: Company's Newest Director Brings Expertise in Commercial and Legal Matters Both in the United States and China; Joins on the Heels of Successful Business Development Trade Mission to China April 18th, 2015
Nanion Technologies Appoints James Costantin as Director of Customer Relations: Nanion is pleased to announce the appointment of Dr. James Costantin as Director of Customer Relations at Nanion Technologies Inc. March 31st, 2015